Histogenics
Histogenics is a Waltham, Massachusetts-based tissue regeneration company developing autologous cartilage implant therapies for joint repair, founded in 2000, supported by approximately $226.5 million in disclosed venture funding, and currently delisted from NASDAQ.
- Company typePrivate
- Founded2000
- HeadquartersWaltham, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Histogenics does
Histogenics was a clinical-stage tissue regeneration company founded in 2000 and headquartered in Waltham, Massachusetts. Per its own positioning, the company was developing breakthrough treatments for long-lasting joint repair, built around an autologous cell-based tissue engineering platform that used a proprietary collagen scaffold seeded with patient-derived chondrocytes to repair damaged cartilage. The company operated as a venture-backed regenerative medicine biotech pursuing FDA approval and eventual commercialization through hospital and orthopedic surgery channels, with intended customers being orthopedic surgeons and patients with focal cartilage lesions of the knee.
The business model followed the standard clinical-stage biopharmaceutical playbook. Histogenics raised approximately $226.5 million in disclosed venture and strategic funding across seven rounds from 2006 through 2018, drawing early corporate validation from orthopedic strategics Howmedica and Stryker and sustained backing from dedicated healthcare investors led by Sofinnova Investments, with proceeds funding preclinical and clinical advancement of its lead cartilage implant program. The company acquired ProChon Biotech in 2011 to broaden its tissue engineering capabilities and was led by founder Shuichi Mizuno and Chairman Garheng Kong. No product revenue, pricing model, or customer segmentation is disclosed in the available data, and the company is currently delisted from NASDAQ under the symbol HSGX with no confirmable active operating status.
Histogenics firmographics
Firmographics- Name
- Histogenics
- Website
- https://histogenics.com
- Company type
- Private
- Founded year
- 2000
- Headcount range
- 51–100 employees
- Short description
- Histogenics is a Waltham, Massachusetts-based tissue regeneration company developing autologous cartilage implant therapies for joint repair, founded in 2000, supported by approximately $226.5 million in disclosed venture funding, and currently delisted from NASDAQ.
- Ownership category
- akta.pro rank
Histogenics industry classification
Industry- Product category
- Regenerative Medicine
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- akta.pro primary industry
- Stem Cell–Based Regenerative Therapies (HLAAAGAA)
- akta.pro secondary industries
- Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE), Cartilage, Bone & Musculoskeletal Regeneration (HLAAAGAH), Stem Cell Therapies (Autologous & Allogeneic) (HLAMANAA), Cell Therapy Manufacturing Services (GMP, autologous/allogeneic) (HLAAAKAC), Veterinary Regenerative Medicine Manufacturing (GMP/CDMO, Cell Processing) (HLAMANAI), Anatomic Pathology & Histopathology (Trial Support) (HLAGAEAC)
Keywords
Where Histogenics is headquartered
LocationHeadquarters
- HQ city
- Waltham
- HQ country
- United States
- HQ region
- North America
Markets served
Histogenics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain
Histogenics product offering
Product offeringCore offering
Histogenics is a tissue regeneration company that develops biological, cell-based treatments intended to provide long-lasting joint repair. Its core work focuses on regenerative therapies for damaged articular cartilage and other joint tissues, with the offering centered on proprietary tissue-engineered therapeutics that surgeons administer to patients suffering from cartilage injuries and degenerative joint conditions.
Product overview
No product information available. The source data contains only a minimal webpage with a broken image server reference and a privacy policy link, with no substantive content about Histogenics's products, services, or offerings.
Differentiator
Problem solved
Functional benefit
Products and services
- Tissue regeneration therapy for joint repair Biological, cell-based treatment developed by Histogenics to provide long-lasting repair of damaged joint surfaces, intended for use by orthopedic specialists treating patients with cartilage injuries and degenerative joint conditions.
Companies that use Histogenics
Customer profileIdeal customer profiles1 record
Histogenics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Histogenics partnerships and signals
Strategic signalRecent moves6 records
Expansion highlights3 records
Histogenics competitors and assessment
Company assessmentBroad incumbents
- Smith & Nephew: Smith & Nephew is a global orthopedic and sports medicine major offering cartilage repair products (including the legacy Osiris Therapeutics cell therapy portfolio), representing a broad incumbent with overlapping capabilities.
- Zimmer Biomet: Zimmer Biomet is a major orthopedic company with a sports medicine and biologics portfolio that competes with Histogenics on cartilage repair and chondrocyte-based therapies for joint preservation.
- Stryker: Stryker is a global orthopedic devices leader and a prior strategic investor in Histogenics (2006 funding round), with a broad portfolio that overlaps cartilage repair, biomaterials, and regenerative adjacencies.
Direct peers
- Anika Therapeutics: Anika develops hyaluronic-acid based viscosupplements and regenerative cartilage therapies (e.g., HYALOFAST, Hyalograft C), competing in the same orthopedic regenerative medicine and tissue-engineering niche.
- Vericel: Vericel markets MACI, the leading autologous cultured chondrocyte product for cartilage repair of the knee, making it the most direct competitor to Histogenics' joint repair platform.
Emerging players
- MiMedx: MiMedx commercializes placental tissue allografts and other regenerative biologics for musculoskeletal and wound care indications, serving as an adjacent emerging player in the orthobiologics market.
- Mesoblast: Mesoblast develops allogeneic cellular medicines for orthopedic and inflammatory indications, making it an emerging regenerative medicine peer with adjacent rather than identical technology.
- InGeneron: InGeneron develops point-of-care autologous adipose-derived regenerative cell therapies for orthopedic and musculoskeletal indications, competing for the same joint-preservation clinical use cases with a different delivery model.
Regional players
- CO.DON: CO.DON develops autologous chondrocyte transplantation (Spherox) for articular cartilage defects in the EU, a direct regional competitor focused primarily on European markets rather than the US.
Others
- CellGenix (SCTbio / Octane Biotech): CellGenix supplies GMP-grade cell and gene therapy manufacturing reagents and services, providing enabling infrastructure used by autologous cell therapy developers such as Histogenics.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key highlights7 records
Customer concentration
Histogenics social profiles
Digital presenceHistogenics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Histogenics leadership team
Management profileNumber of profiles
Profiles2 records
Histogenics funding detail
Funding detailFunding overview
Funding rounds7 records
Investors11 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Histogenics M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Histogenics
What does Histogenics do?
Histogenics is a tissue regeneration company that develops biological, cell-based treatments intended to provide long-lasting joint repair. Its core work focuses on regenerative therapies for damaged articular cartilage and other joint tissues, with the offering centered on proprietary tissue-engineered therapeutics that surgeons administer to patients suffering from cartilage injuries and degenerative joint conditions.
When was Histogenics founded?
Histogenics was founded in 2000. It employs 51 to 100 people.
Where is Histogenics based?
Histogenics is headquartered in Waltham, United States, in the North America region.
Who are Histogenics's main competitors?
Broad incumbents on record are Smith & Nephew, Zimmer Biomet and Stryker. Direct peers are Anika Therapeutics and Vericel. Emerging players are MiMedx, Mesoblast and InGeneron. CO.DON is listed as a regional player. CellGenix (SCTbio / Octane Biotech) is listed as an others.
Does Histogenics have an API?
No public API is recorded for Histogenics.
What industry is Histogenics in?
Histogenics's product category is Regenerative Medicine. Its primary akta.pro industry code is HLAAAGAA, Stem Cell–Based Regenerative Therapies, with a secondary code of HLAAABAE, Stem Cell Therapies (MSC/iPSC/HSC-derived). Its NAICS code is 325414.